Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics is a clinical-stage biotechnology company developing novel anti-infective therapies to combat the global threat of antimicrobial resistance. The company's primary technology, the Bisphosphocin® platform, consists of synthetic, broad-spectrum antimicrobials that rapidly disrupt microbial cell membranes to eradicate bacteria and fungi without inducing resistance. Its lead candidate, Nu-3, is a topical gel currently in Phase 2 clinical trials for the treatment of infected diabetic foot ulcers. Additionally, the company is advancing a nanoRNA (nRNA) platform for gene-silencing applications in viral diseases such as influenza and hepatitis. Lakewood-Amedex aims to provide fast-acting, locally delivered treatments that improve patient outcomes while reducing systemic side effects.